Taiwan has the potential to become a biomedical powerhouse in three years if the nation can continue to provide capital access to the industry, Chen Lan-bo (陳良博), cofounder of AIDS drug developer TaiMed Biologics Inc (中裕新藥), said last week.
Chen, an emeritus at Harvard Medical School, expects new drug companies in Taiwan could generate US$30 billion in revenue a year, with 10 companies, including TaiMed, OBI Pharma Inc (台灣浩鼎), Taiwan Liposome Co (台灣微脂體) and TaiGen Biotechnology Co (太景生技) able to acquire drug permits over the next three years.
Chen said his optimism should encourage investors, including government officials, to continue funding the industry and help attract major global pharmaceutical companies to seek for potential collaboration opportunities here.
MIRACLE
“It is a miracle for the capital market in Taiwan to become so supportive to the industry,” Chen said at a press conference on Saturday. “The phenomenon was totally unimaginable five to 10 years ago.”
In 2007, Chen and David Ho (何大一), well known for his study on combination therapy to treat AIDS, founded TaiMed in Taipei with investments from the state-run National Development Fund and the private sector.
Chen said funding is especially important to the industry, but relying on stock markets might not be enough. Rather, private hedge funds or the government should also play a role to offer money in need, he said.
“The government should establish rules for local insurance companies to invest their money in the biotechnology industry, as pension funds in the US are one of the main sources for capital,” he said.
INVESTMENT TALKS
About eight years ago, when Chen worked as senior scientific adviser for New York-based hedge fund Caxton Health Holdings, he had talks with nine Taiwanese insurance companies about investing in biomedical firms.
However, their investment plans were denied by the government, as officials perceived making investment in the industry as too risky, he said.
According to Chen, the nine companies had idle funds of about NT$8 trillion to NT$15 trillion (US$267 trillion to US$501 trillion) at that time, and even 1 percent of the money would be helpful to many biomedical firms.
Asked whether there is a bubble for the biomedical industry in Taiwan, Chen said the same question was asked in the US in the past when the industry began to flourish.
“However, for the industry in Taiwan to really make some achievements, to have enough people believing the industry would be successful is a precondition,” he said.
At the conference on Saturday, Ho, the scientific director and CEO of Aaron Diamond AIDS Research Center at the Rockefeller University, said that for Taiwan to have a strong biotechnology industry like the US, the nation should adopt a more bottom-up decisionmaking process to allow scientists “the freedom to roam and explore,” rather than requiring them to focus on topics policymakers and officials are interested in.
LEARNING FROM FLIES
“We learn something about the immune system from the studies of flies. A fruit fly taught us that there is a whole part of our immune system that 20 years ago we didn’t know anything about,” Ho said. “It is uninhibited research that makes scientific breakthroughs, and important products emerge from those breakthroughs.”
Unlike companies in South Korea, where large private firms are backed by the government, the success of small biotechnology firms in Taiwan is the result of contributions from private citizens, including Samuel Yin (尹衍樑), chairman of Ruentex Group (潤泰集團) who helped fund TaiMed, Ho said, adding that although these firms are still young and deliver “more promises than products,” they will be more successful in coming years.
DAMAGE REPORT: Global central banks are assessing war-driven inflation risks as the law of unintended consequences careens around the world, spiking oil prices Central banks from Washington to London and from Jakarta to Taipei are about to make their first assessments of economic damage after more than two weeks of conflict between the US and Iran. Decisions this week encompassing every member of the G7 and eight of the world’s 10 most-traded currency jurisdictions are likely to confirm to investors that the specter of a new inflation shock is already worrying enough to prompt heightened caution. The US Federal Reserve is widely expected to do exactly what everyone anticipated weeks ahead of its March 17-18 policy gathering: hold rates steady. The narrative surrounding that
PRICE HIKES: The war in the Middle East would not significantly disrupt supply in the short term, but semiconductor companies are facing price surges for materials Taiwan’s semiconductor companies are not facing imminent supply disruptions of essential chemicals or raw materials due to the war in the Middle East, but surges in material costs loom large, industry association SEMI Taiwan said yesterday. The association’s comments came amid growing concerns that supplies of helium and other key raw materials used in semiconductor production could become a choke point after Qatar shut down its liquefied natural gas (LNG) production and helium output earlier this month due to the conflict. Qatar is the second-largest LNG supplier in the world and accounts for about 33 percent of global helium output. Helium is
About 1,000 participants, including more than 200 venture capitalists, joined the Taiwan Demo Day in Silicon Valley on Saturday, the largest iteration to date of the event held ahead of Nvidia Corp’s annual GPU Technology Conference which runs from today to Thursday. Taiwan Demo Day, co-organized by the Taiwan Next Foundation and the Startup Island Taiwan Silicon Valley Hub, took place at the Computer History Museum in California, showcasing 12 teams focused on physical artificial intelligence (AI) and agentic AI technologies. Katie Hsieh (謝凱婷), founder of the Taiwan Next Foundation, said the event highlighted the strength of the Taiwan-US start-up ecosystem, with
DOMESTIC COMPONENT: Huang identified several Taiwanese partners to be a key part of Nvidia’s Vera Rubin supply chain, including Asustek, Hon Hai and Wistron Nvidia Corp chief executive officer Jensen Huang (黃仁勳), addressing crowds at the company’s biggest annual event, unveiled a variety of new products while predicting that its flagship artificial intelligence (AI) processors would help generate US$1 trillion in sales through next year. During a two-and-a-half-hour keynote address, Huang announced plans to push deeper into central processing units (CPUs) — Intel Corp’s home turf — and introduced semiconductors made with technology acquired from start-up Groq Inc. The company even said it was developing chips for data centers in outer space. At the heart of Huang’s speech was the message that demand for computing power
RSS